acalabrutinib

	acalabrutinib
Trade Name
Orphan Indication	Chronic lymphocytic leukemia
USA Market Approval	USA
USA Designation Date	2015-05-13 00:00:00
Sponsor	Acerta Pharma BV;Molenstraat 110, 5342 CC Oss;